Respiratory Syncytial Virus Infections
Conditions
Keywords
Respiratory Syncytial Virus (RSV), Adjuvated RSVPreF3 vaccine, Solid organ transplant (SOT), Kidney SOT, Lung SOT, Immunocompromised (IC) patients, Humoral immune response, Safety, Reactogenicity
Brief summary
This study evaluates persistence of the immune response of the adjuvanted RSV vaccine and the safety and immunogenicity following revaccination in adults 18 years of age and above who received lung or kidney transplant.
Detailed description
Lung or kidney transplant recipients undergoing chronic immunosuppressive therapy, who received 1 (IC\_1 group) and 2 (IC\_2 group) doses of the adjuvanted RSVPreF3 vaccine in the RSV OA=ADJ-023 study \[parent study; NCT05921903\], will receive an additional dose of the adjuvanted RSVPreF3 vaccine in the current study. As pre-assigned in protocol, the participants that received 1 dose and 2 doses of adjuvanted RSVPreF3 vaccine in the parent study will be analysed separately in the current study for the immune response analyses, and under an overall group (IC Revaccination group) for the demographic and safety analyses.
Interventions
BIOLOGICALAdjuvanted RSVPreF3 vaccine
1 dose of adjuvanted RSVPreF3 vaccine administered intramuscularly at Visit 1 (Day 1).
Sponsors
GlaxoSmithKline
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Masking description
This is an open-label study.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants of the RSV OA=ADJ-023 study from the Per Protocol Set (Visit 3 for participants in IC\_1 and Visit 4 for participants in IC\_2 group), who received either 1 or 2 doses of the adjuvanted RSVPreF3 vaccine and for whom the immunogenicity data are available. * Participants who, can and will comply with the requirements of the protocol (e.g., completion of the paper diary cards (as applicable), return for follow-up visits, ability to access and utilize a phone or other electronic communications, have regular contact to allow evaluation during the study). * Written or witnessed informed consent obtained from the participant prior to performance of any study-specific procedure. * Female participants of nonchildbearing potential may be enrolled in the study. Non childbearing potential is defined as hysterectomy, bilateral oophorectomy, bilateral salpingectomy, and post-menopause. * Female participants of childbearing potential may be enrolled in the study if the participant: * has practiced adequate contraception from 1 month prior to study intervention administration, and * agreed to continue adequate contraception until 1 month after study intervention, and * has a negative pregnancy test on the day of and prior to study intervention administration. * Participant who has received an ABO compatible allogeneic kidney or lung transplant (allograft) more than 12 months (365 days) prior to the study intervention administration. * Participant receiving maintenance immunosuppressive therapy for the prevention of allograft rejection. Specific inclusion criteria for kidney transplant (KTx) patients • Participant with stable kidney function, stability defined as less than 20% variability between last two results of eGFR or in the opinion of the investigator after investigator review of more than the last two results of eGFRs and based on medical history. Specific inclusion criteria for lung transplant (LTx) patients • Participant with stable lung function, with stability defined as the stability in the FEV1 compared to post-transplant baseline FEV1 and based on medical history of the last 3 months, in the opinion of the investigator.
Exclusion criteria
Medical conditions * Any history of dementia or any medical condition that moderately or severely impairs cognition. * Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival up to study end). * History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention * Acute or chronic clinically significant cardiovascular or hepatic functional abnormality, as determined by physical examination or laboratory screening tests. * Recurrent or uncontrolled neurological disorders or seizures. Participants with medically controlled chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol. * Any condition which, in the judgment of the investigator, would make IM injection unsafe. * Any other clinical condition that might pose additional risk to the participant due to participation in the clinical study. Prior/Concomitant therapy * Vaccination with RSV-antigen containing vaccine after 1 or 2 doses received in the RSV OA=ADJ-023 study. * Use of any investigational or non-registered product (drug, vaccine, or medical device) other than the study intervention administration during the period beginning 30 days before the study intervention administration (Day -30 to Day 1), or their planned use during the study period (up to Month 12). * Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before the study intervention administration and ending 30 days after the study intervention administration\*. In the case of COVID-19 and inactivated/subunit/split influenza vaccines, this time window can be decreased to 14 days before and after study intervention administration. * If emergency mass vaccination for an unforeseen public health threat (e.g., a pandemic) is recommended and/or organized by the public health authorities outside the routine immunization program, the time period of 30 days described above can be reduced, if necessary for that vaccine, provided it is used according to the local governmental recommendations and that the Sponsor is notified. Prior/Concurrent clinical study experience • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention (drug/invasive medical device). Other
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| RSV-A neutralizing titers expressed as Geometric mean titers (GMTs) | At Visit 1 (Day 1) of the current study | RSV-A neutralizing titers are given as GMTs and are expressed as Estimated Dilution 60 (ED60). GMT is calculated by taking the anti-log of the mean of the log titer transformations. |
| RSV-B neutralizing titers expressed as GMTs | At Visit 1 (Day 1) of the current study | RSV-B neutralizing titers are given as group GMTs and are expressed as ED60. GMT is calculated by taking the anti-log of the mean of the log titer transformations. |
| RSV-A neutralizing titers expressed as Mean geometric increase (MGI) | At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study | MGI is defined as the geometric mean of the within participant ratios of two timepoints (ie., ratio of titers observed at Visit 1 over titers observed 30 days post last dose in the RSV OA=ADJ-023 parent study). |
| RSV-B neutralizing titers expressed as MGI | At Visit 1 (Day 1) of the current study over 30 days post last dose in the RSV OA=ADJ-023 study | MGI is defined as the geometric mean of the within participant ratios of two timepoints (ie., ratio of titers observed at Visit 1 over titers observed 30 days post last dose in the RSV OA=ADJ-023 parent study). |
| RSV-A neutralizing titers expressed as GMTs | At Visit 2 (Day 31) of the current study | RSV-A neutralizing titers are given as GMTs and are expressed as ED60. GMT is calculated by taking the anti-log of the mean of the log titer transformations. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMT ratio of RSV-A neutralizing titers | At Visit 1 (Day 1) of the current study | RSV-A neutralizing titers are given as group GMTs and are expressed as ED60. GMT is calculated by taking the anti-log of the mean of the log titer transformations. |
| GMT ratio of RSV-B neutralizing titers | At Visit 1 (Day 1) of the current study | RSV-B neutralizing titers are given as group GMTs and are expressed as ED60. GMT is calculated by taking the anti-log of the mean of the log titer transformations. |
| RSV-A neutralizing titers expressed as MGI | At Visit 2 (Day 31) over Visit 1 (Day 1) and at Visit 3 (Day 180) over Visit 1 (Day 1) [each visit of the current study] | MGI is defined as the geometric mean of the within participant ratios of two timepoints (ie., ratio of titers observed at Visit 2 over titers observed at Visit 1, and Visit 3 over Visit 1). |
| RSV-B neutralizing titers expressed as MGI | At Visit 2 (Day 31) over Visit 1 (Day 1) and at Visit 3 (Day 180) over Visit 1 (Day 1) [each visit of the current study] | MGI is defined as the geometric mean of the within participant ratios of two timepoints (ie., ratio of titers observed at Visit 2 over titers observed at Visit 1, and Visit 3 over Visit 1). |
| Number of participants reporting each solicited administration site event | Visit 1 (Day 1 [day of revaccination]) to Day 7 of the current study | Solicited administration site events assessed are pain, redness and swelling. |
| Number of participants reporting each solicited systemic event | Visit 1 (Day 1 [day of revaccination]) to Day 7 of the current study | Solicited systemic events assessed are fever, headache, myalgia (muscle pain), arthralgia (joint pain) and fatigue (tiredness). |
| Number of participants reporting unsolicited adverse events (AEs) | Visit 1 (Day 1 [day of revaccination]) to Day 30 of the current study | An unsolicited AE is an AE that was either not included in the list of solicited events or could be included in the list of solicited events but with an onset outside the specified period of follow-up for solicited events. Unsolicited AEs include both serious and nonserious AEs. |
| Number of participants reporting any serious adverse events (SAEs) | Visit 1 (Day 1 [day of revaccination] to Visit 3 (Day 180) of the current study | An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes. Any SAE = occurrence of the SAE regardless of relation to study vaccination. |
| Number of participants reporting related SAEs and fatal SAEs | Visit 1 (Day 1 [day of revaccination] to study end (Day 365) of the current study | Related SAE = SAE assessed by the investigator as related to the study vaccination. Fatal SAE = occurrence of a fatal SAE regardless of relation to study vaccination. |
| Number of participants reporting any Potential immune-mediated disease (pIMDs) and related pIMDs | Visit 1 (Day 1 [day of revaccination] to study end (Day 365) of the current study | pIMDs are a subset of Adverse events of special interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology. Any pIMDs = occurrence of the pIMDs regardless of relation to study vaccination. Related pIMDs = pIMDs assessed by the investigator as related to the study vaccination. |
| Number of participants reporting AESIs specific to kidney and lung SOT patients | Visit 1 (Day 1 [day of revaccination] to study end (Day 365) of the current study | AESIs specific to kidney and lung SOT patients include signs of transplant/allograft rejection. |
Countries
Australia, Canada, Germany, Italy, Japan, South Korea, Spain, United States
Outcome results
None listed